Abstract 48P
Background
Sentinel lymph node biopsy (SLNB) in post-neoadjuvant chemotherapy (NACT) has demonstrated a higher false negative rate (FNR) compared to early breast cancer. This might result from a non-uniform pattern of tumour regression in SLN and Non-SLN within the axilla. SLNB can assess SLN alone by itself, but preoperative axillary ultrasound (AUS) can also determine the characteristics of Non-SLN. We studied whether axillary staging in post-NACT patients could be improved by combining AUS and SLNB to reduce false negative cases.
Methods
It was a single-centre, prospective study that was conducted between September 2020 and June 2022. All Post-NACT, clinically node-negative(cN0) patients who were scheduled for surgery were enrolled and underwent AUS. AUS normal node patients underwent SLNB using fluorescein and methylene blue followed by Axillary Lymph Node Dissection (ALND). We evaluated the AUS's Positive Predictive Value (PPV), Negative Predictive Value (NPV) and FNR in cN0 patients. The FNR of SLNB was calculated in patients who had cN0 and AUS normal nodes.
Results
cN0 was found in 62 patients out of 136 post-NACT patients.AUS had PPV and NPV of 90.6% and 76.6%, respectively. The FNR for AUS alone was 19.4% (7/36). Loss of fatty hilum was found to have a PPV of 89.3% and a sensitivity of 70%, making it the most reliable marker of nodal metastasis. Methylene blue allergy was observed in 1 patient. The FNR of SLNB was 8.6% (2/23) for the patients who had been selected for SLNB based on AUS normal nodes.
Conclusions
AUS alone or SLNB alone is insufficient to determine axilla node-negative status and can't omit ALND because each has a high FNR (>10%). If AUS findings are considered for selecting patients for SLNB, it reduces its FNR to below 10% and improves the accuracy of axillary staging in post-NACT patients.
Clinical trial identification
Clinical Trials Registry (India) number- CTRI/2020/10/028337.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
415P - Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay
Presenter: Steven Tucker
Session: Poster Display
Resources:
Abstract
416P - Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response
Presenter: Jiangang Zhang
Session: Poster Display
Resources:
Abstract
417P - Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle East
Presenter: Shaheenah Dawood
Session: Poster Display
Resources:
Abstract
418P - Decoding the intricate cellular makeup of immune-related adverse events using single-cell and spatial analysis
Presenter: Dmitrii Shek
Session: Poster Display
Resources:
Abstract
420P - Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment
Presenter: Xuchao Zhang
Session: Poster Display
Resources:
Abstract
421P - Comprehensive genomic profiling (CGP) unravels somatic BRCA (sBRCA) and homologous recombinant repair (HRR) gene alterations across multi-cancer spectrum
Presenter: Ramya Kodandapani
Session: Poster Display
Resources:
Abstract
422P - CD8Teff distinguished tumor immunotyping heterogeneity and enables precision immunotherapy
Presenter: luhui Mao
Session: Poster Display
Resources:
Abstract
423P - Insights into clinically actionable biomarkers in an Indian cancer cohort of 1000 patients using comprehensive genomic profiling (CGP)
Presenter: Mithua Ghosh
Session: Poster Display
Resources:
Abstract
424P - MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
Presenter: Brigette Ma
Session: Poster Display
Resources:
Abstract
425P - Engineered <italic>Lactococcus lactis</italic> as a personalized cancer vaccine platform induces antitumour immunity via membrane-inserted peptide for neoantigens
Presenter: Meng Zhu
Session: Poster Display
Resources:
Abstract